Private Advisor Group LLC Sells 634 Shares of Eli Lilly and Company $LLY

Private Advisor Group LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 0.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 86,496 shares of the company’s stock after selling 634 shares during the quarter. Private Advisor Group LLC’s holdings in Eli Lilly and Company were worth $79,556,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Optas LLC lifted its holdings in shares of Eli Lilly and Company by 1.3% during the first quarter. Optas LLC now owns 3,937 shares of the company’s stock worth $3,621,000 after buying an additional 49 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Eli Lilly and Company in the first quarter valued at about $30,336,000. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in shares of Eli Lilly and Company by 60.6% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 344,542 shares of the company’s stock valued at $316,899,000 after acquiring an additional 130,006 shares in the last quarter. Proathlete Wealth Management LLC increased its position in Eli Lilly and Company by 37.3% during the first quarter. Proathlete Wealth Management LLC now owns 232 shares of the company’s stock worth $214,000 after acquiring an additional 63 shares during the period. Finally, Elevation Point Wealth Partners LLC increased its position in Eli Lilly and Company by 106.2% during the first quarter. Elevation Point Wealth Partners LLC now owns 42,234 shares of the company’s stock worth $38,846,000 after acquiring an additional 21,749 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Coverage highlighted Eli Lilly as a leader in GLP-1 therapies with an expanding pipeline and diversified growth strategy, reinforcing the bull case despite the stock’s premium valuation. Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• Positive Sentiment: Shares were lifted by optimism around GLP-1 Medicare inclusion and strong reported results, which investors view as supportive of continued demand and revenue growth. Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
• Positive Sentiment: Another bullish note argued that artificial intelligence could become a long-term growth tailwind for Eli Lilly by improving drug development and operational efficiency. AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
• Positive Sentiment: Repeated mentions in pharmaceutical and medical stock roundups suggest Lilly remains one of the sector’s preferred large-cap names for investors seeking growth exposure. Pharmaceutical Stocks To Follow Now – July 2nd
• Positive Sentiment: Additional commentary pointed to Lilly’s appeal to long-term, high-conviction investors, including billionaire hedge fund manager Cliff Asness, adding to the stock’s credibility as a favored healthcare holding. Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ?
• Neutral Sentiment: One item noted a leadership change at Lilly Korea, which appears operationally routine and unlikely to move the stock on its own. Eli Lilly Korea names Komasu Seiya new representative
• Neutral Sentiment: General industry pieces about pharmaceutical growth and the sector’s $2 trillion sales trajectory are supportive of sentiment, but they do not add a specific new catalyst for Lilly. Can pharma sustain its $2T trajectory?

Eli Lilly and Company Trading Down 0.5%

Shares of Eli Lilly and Company stock opened at $1,208.37 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,238.00. The company has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 42.93, a PEG ratio of 1.51 and a beta of 0.51. The firm’s 50-day moving average price is $1,065.45 and its two-hundred day moving average price is $1,028.14.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the company earned $3.34 EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 35.74 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Rothschild & Co Redburn boosted their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Friday, June 5th. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Bank of America boosted their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,235.07.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.